Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price336.94 USD
Fair value314.74
Ethical score85.8/100
RatingOVERVALUED
Our investment reviews on this name
2026-09-17Read Accumulation336.94+0.0% to today ✓
2026-08-18Read Markdown351.02-4.0% to today ✓
2026-07-02Read Accumulation314.50+7.1% to today ✓
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
West Pharmaceutical Services holds its Accumulation at $336.94. The statistical read favours the sellers, held for 22 days.
As held on the ledger · 2026-09-09
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 22 days
Price at the screen
$336.94
Valuation
43.20 trailing · 33.77 forward price to earnings
Values screen
PASS· score 85.8
Beta
1.14
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
7.52%
Below 33%
Interest-bearing debt is just 7.5% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
4.97%
Below 33%
Cash held in interest-bearing accounts and securities is 5.0% of assets, under the one-third limit.
Pass
Receivables
31.98%
Below 49%
Money owed to the company is 32.0% of assets, under the 49% limit.
Pass
Revenue purity
0.57%
Below 5%
Only 0.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OVERVALUED: it trades above our $314.74 fair value estimate, moderate competitive moat, 13.80% revenue growth.
Fair value range in USD, drawn from the 2026-09-09 screen. The gold marker is the market price at the same screen. The price runs 6.6% above the base estimate.
Third-party analyst targets: 15 covering, consensus Strong Buy. The average target sits +22% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-09 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
The quiet supplier behind every safe injection
Every time a biologic reaches a patient, it travels inside packaging that must not fail. West Pharmaceutical Services builds those vials and delivery systems across the Americas, Europe and Asia, posting 21% revenue growth, 17% profit margins and 19% ROE.
Those results are respectable, yet the shares sit 16% above our fair value at a 37 times forward earnings multiple. The market is already paying for strong growth that may not repeat at the same pace, leaving the stock overvalued on plain numbers.
A moderate moat and clean ethical screen reduce some concerns, but high valuation still leaves investors exposed if drug spending slows or input costs rise. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
WST trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 4.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 46%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it buy, with a mean price target of $350.
2026-08-18Markdown · changed$351.02+11.6%Entry 4
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 11.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 46%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it buy, with a mean price target of $350.
2026-07-18Accumulation$314.50+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 46%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it buy, with a mean price target of $350.
2026-07-03Accumulation$314.50+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Accumulation$314.50Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
